Dash Bio Scales Rapid Bioanalysis Platform with New 24,000 sq. ft. GLP Facility in Waltham

New updates have been reported about Dash Bio.

Dash Bio has materially expanded its operating capacity and growth runway by moving into a new 24,000-square-foot GLP-compliant facility in Waltham, Massachusetts, a more than fivefold increase over its prior footprint and now fully operational with no onboarding delay for new work. The Boston-area lab is purpose-built around automation-first workflows that replace traditional manual CRO processes, enabling Dash Bio to maintain its value proposition of delivering preclinical and GLP-compliant bioanalysis results in days rather than the industry’s typical 4–6 weeks, while adding significant infrastructure for long-term sample storage and additional instrumentation to support larger and more complex programs.

For biopharma clients, the expansion is aimed at removing a key bottleneck in drug development timelines by combining three-day turnaround options, standardized automation, and transparent, predictable pricing without hidden fees or change-order friction, improving both speed and budget visibility for R&D planning. CEO Dave Johnson, formerly Chief Data and AI Officer at Moderna, said the new facility allows Dash Bio to serve more biotech companies that are “tired of waiting months for data that should take days,” underscoring the company’s strategy to deliver rapid bioanalysis at scale. The Waltham build-out follows $17.5 million in capital raised since Dash Bio’s 2024 founding by Johnson, COO Ander Tallett, and CSO Ely Porter, and positions the company to capture rising demand from biotech firms frustrated with legacy CRO timelines across therapeutic areas. Strategically, the expanded GLP footprint, automation-centric design, and scalable storage infrastructure strengthen Dash Bio’s competitive differentiation as a tech-enabled bioanalysis CRO and provide a platform for further volume growth, deeper client penetration, and potential future service-line expansion.